Nuvalent Announces First Patient Dosed in ARROS-1 Phase 1/2

/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer,...

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , Christopher Turner , James Porter , Linkedin , Nuvalent Inc , Twitter , Nasdaq , Prnewswire Nuvalent Inc , Exchange Commission , Company Quarterly Report On Form , Product Development Regulatory Affairs For Nuvalent , Chief Medical Officer , Darlene Noci , Senior Vice President , Product Development , Regulatory Affairs , Chief Executive Officer , Private Securities Litigation Reform Act , Quarterly Report , Nuvalent , Nc , Health Care Amp Hospitals , Medical Pharmaceuticals , Biotechnology , Clinical Trials Amp Medical Discoveries ,